Tuberculosis Drug Accelerator

Overview of Activities and Portfolio

"who, why, what, how, by when and where are we now"

Steve Berthel

What is the Tuberculosis Drug Accelerator?

Colorado State

Calibr

The TBDA is a groundbreaking partnership between:

A M

- 8 Pharmaceutical companies good obvie Lilly Some Merck (Some AstraZeneca) AstraZeneca
- 5 Major Universities (
- 2 Research Institutes) 0 R 1
- I National Institute NIH National Institute of Allergy and Infectious Diseases
- I non profit PDP TBALLIANCE GLOBAL ALLIANCE FOR TB DRUG DEVELOPM
- With participation from:
 - Bill and Melinda Gates Foundation
- Managed through:
 - The CEO roundtable at the New Venture Fund newenturefund



DUNDEE

TBDA is a quasi-biotech

<u>Somewhat Biotech like</u>

- Discovery, preclinical and early clinical capabilities
- Multiple projects at multiple centers covering different modes of action
- Funding and portfolio management oversight


Fairly Unique

- Comprised of normally competitive organizations that share information and resources at an unprecedented level
- Investigating a single disease from many, many angles
- Output has global access requirements


Why have a TBDA?

- TB is one of the world's leading infectious killers, disproportionately affecting developing countries:
 - 1.4 million deaths in 2015
 - 10.4 million new infections in 2015
 - 480,000 MDR TB cases in 2015
- First-line therapies for TB are antiquated and inadequate, taking 6 months to cure patients
- The current six month regimen contributes to high treatment default rates that can lead to:
 - increased transmission
 - drug resistance
 - death
- The world needs a shorter, safer TB drug regimen






Why have a TBDA?



- Limited investment in TB biology and drug discovery
- Lack of understanding of how to improve therapy
- Few well validated targets
- Poor assays to screen for drugs
- No new first line drugs in 50 years (safety of recent entries limit use)
- Resistance to only true sterilizing and treatment shortening agent
- Limited Candidates


What should we focus on?

- Current TB regimens drive down bacterial levels quickly, but require months of treatment to rid the body of all TB
- The only way to overcome this persistence is through a shorter more effective regimen
- GOAL-To generate multiple, mechanistically distinct TB candidates sufficient to advance a drug regimen to a one month clinical POC by 2024
- Need to create a balanced portfolio
 - Novel mechanisms
 - Sequestered sites (granulomas, cavities)
 - Tolerant sub-populations
 - Safety
 - Resistance




How will this be accomplished?

- The current research paradigm in ineffective
- No New first-line TB drug regimens in 50 years




How will this be accomplished?

- By a new approach that addresses bottlenecks in historic TB drugs development
- In this way only the best candidates advance





TBDA organization

- 17 current members
- 8 subteams



TBDA Discovery/Preclinical Development





TBDA Discovery/Preclinical Capabilities




- Libraries
 - Pharma partners (Sanofi, Merck, Bayer, AbbVie, Lilly, AstraZeneca, GSK, Pfizer)
 - Other (MMV, BioFocus)
- Target
 - ID & validation (Weill Cornell, Texas A&M)
 - Crystallography (Texas A&M)
 - Screening (IDRI, Texas A&M)
- Whole cell
 - Replicating, multiple C source (Weill Cornell, IDRI, NIH)
 - Non-replicating (Weill Cornell)
 - Low pH (Weill Cornell, IDRI, NIH)

TBDA Discovery/Preclinical Capabilities



- Medicinal Chemistry (GSK, Merck, Sanofi, Lilly, AbbVie, UCT, Dundee, CROs)
- Animal Models
 - Acute/Chronic BalbC (GSK, Sanofi, CSU)
 - Kramnik (CSU)
 - Marmoset (NIH)
- PK, Tox
 - Caseium penetration (Rutgers)
 - Metabolomics (Weill Cornell)
 - ADME, PK (Pharma, CROs)
 - In vitro/in vivo Tox (Pharma, CROs)

TBDA Discovery/Preclinical Capabilities



- Lead(s) selected
 - Efficacy in advanced and/or combination models (Pharma, CSU, NIH, non-TBDA collaborators)
 - In vitro tox (CROs)
 - Non-GLP tox studies (CROs)
- Preclinical Candidate Selection (TB Alliance, Gates Foundation, Pharma)
- Preclinical Candidate Profiling
 - IND enabling studies (Pharma, CROs)
 - CMC (Pharma, CROs)
- Clinical
 - Study design (TB Alliance, Pharma)
 - Combination study design (TB Alliance)
 - IND Preparation (TB Alliance, Pharma)




- Screens
 - Whole cell phenotypic screening against corporate collections complete
 - Conditional screening (carbon source, pH, low O₂) continues
 - Special library screening continues
 - Biochemical (target-based) screening continues
- Hits
 - >200 compound series identified to date
 - ~10 currently under triage
 - ~20 currently under hit assessment



Lead Identification


- ~30 projects in hit to lead stage
- ~60% with known targets
 - MmpL3
 - QcrB
 - RNA polymerase





Lead Optimization

- ~10 projects in Lead Optimization
- Almost all with known targets
 - DprE1
 - MmpL3
 - InhA






Preclinical Development

3 projects from the TB Alliance have identified candidates

- DprE1 inhibitor TBA-7371
- Oxazolidinone TBI-223
- Diarylquinoline TBAJ-587



How can the TBDA and CPTR better connect?

- Align meetings
 - Back to back if possible (TBDA meets semi-annually, 1 US based, 1 rest of world)
 - Assure no overlap- encourage co-participation when possible
- Provide clinical data on "front runners" to instruct preclinical back-up projects
- Provide clinical data to help refine, and make more predictive, TB animal models

In Conclusion

- The TBDA is a novel collaboration of 17 research organizations with the goal of discovering multiple mechanistically distinct TB candidates sufficient to advance a drug regiment to a 1 month POC by 2024
- Excellent progress has been made to date, with 3 preclinical candidates identified
- Partnerships such as the TBDA show how industry and others can work together in new ways to support global health innovation
- The TBDA model is being applied to other disease areas that lack incentives for research or require combination drug therapies
- Opportunities exist to use clinical data to inform preclinical projects